阅读说明：本技术 胰高血糖素样肽2(glp-2)类似物的制剂 (Formulations of glucagon-like peptide 2(GLP-2) analogs ) 是由 利塞·吉姆 克拉斯·梅兰德 埃娃·霍恩·默勒 于 2019-09-27 设计创作，主要内容包括：描述了GLP-2类似物的液体制剂,其使得GLP-2类似物适合于作为液体长期储存和/或使得GLP-2类似物特别适合于通过药物递送装置来递送。还描述了可用于制备液体制剂的包含胰高血糖素样肽2(GLP-2)类似物的乙酸盐的固体组合物。这些液体制剂的开发基于以下发现：来源于GLP-2类似物的制剂中存在的乙酸盐对所述制剂的黏度具有影响：在GLP-2类似物在2至8℃下长期储存期间,共价寡聚体形成的浓度依赖性负相关地依赖于GLP-2类似物浓度的提高；并且制剂中使用的GLP-2类似物与现有技术中针对重构的粉末状或冻干的GLP-2组合物常用的磷酸盐缓冲剂不相容。(Liquid formulations of GLP-2 analogs are described that make GLP-2 analogs suitable for long-term storage as a liquid and/or make GLP-2 analogs particularly suitable for delivery by drug delivery devices. Solid compositions comprising an acetate salt of a glucagon-like peptide 2(GLP-2) analog that are useful for preparing liquid formulations are also described. The development of these liquid formulations was based on the following findings: the acetate present in the formulation derived from the GLP-2 analogue has an effect on the viscosity of the formulation: the concentration-dependent negative dependence of covalent oligomer formation during long-term storage of a GLP-2 analogue at 2 to 8 ℃ is dependent on an increase in the concentration of the GLP-2 analogue; and the GLP-2 analogs used in the formulation are incompatible with phosphate buffers commonly used in the prior art for reconstituted powdered or lyophilized GLP-2 compositions.)